Piramal Pharma Limited (PPLPHARMA.NS) Bundle
A Brief History of Piramal Pharma Limited
Piramal Pharma Limited, a subsidiary of the Piramal Group, focuses on providing innovative solutions across various pharmaceutical sectors. Founded in 1988, Piramal Enterprises originally established the pharmaceutical division, which underwent notable restructuring and growth over the years.
In 2019, Piramal Pharma was demerged from Piramal Enterprises, creating a standalone entity. This strategic move was aimed at enhancing operational efficiency and focusing on growth in the pharmaceutical sector. As of March 2023, Piramal Pharma reported a revenue of approximately INR 10,700 crore (around USD 1.3 billion), positioning itself as one of India's leading pharma companies.
The company operates through two main segments: Piramal Pharma Solutions, which offers contract development and manufacturing services (CDMO), and Piramal Critical Care, focusing on critical care drugs and hospital products.
In terms of market performance, Piramal Pharma listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker symbol 'PPL'. As of October 2023, the stock price hovered around INR 800, with a market capitalization of approximately INR 32,000 crore (around USD 3.9 billion).
| Fiscal Year | Revenue (INR Crore) | Net Profit (INR Crore) | EBITDA Margin (%) | Market Cap (INR Crore) |
|---|---|---|---|---|
| 2020 | 8,200 | 650 | 14.5 | 28,000 |
| 2021 | 9,500 | 850 | 16.8 | 30,500 |
| 2022 | 10,200 | 900 | 17.5 | 31,700 |
| 2023 | 10,700 | 1,050 | 18.5 | 32,000 |
In recent years, the company has expanded its global footprint, entering markets in North America, Europe, and Asia. Piramal Pharma Solutions operates nine manufacturing facilities and two R&D centers worldwide, enhancing its capacity to deliver diverse pharmaceutical products.
Moreover, the company has prioritized research and development, allocating roughly 7% of revenue to R&D expenditure in FY 2022. This commitment has led to the development of several new generic drugs, biosimilars, and specialty products aimed at treating complex diseases.
In 2021, Piramal Pharma acquired the contract development and manufacturing organization (CDMO) business of the US-based company, enhancing its capabilities in sterile injectable and complex formulations.
Overall, Piramal Pharma Limited has positioned itself to leverage the growing global pharmaceutical market. As of 2023, the global pharmaceutical market is valued at approximately USD 1.5 trillion, with an expected CAGR of around 4-5% over the next five years. Piramal Pharma aims to capture a significant share of this expanding market through strategic expansions and innovation.
A Who Owns Piramal Pharma Limited
Piramal Pharma Limited, a prominent player in the pharmaceutical industry, operates under the umbrella of the Piramal Group. As of the latest data, the ownership structure is notable for its distribution among institutional, individual, and promoters.
Ownership Structure
| Category | Ownership Percentage |
|---|---|
| Promoter and Promoter Group | 66.8% |
| Foreign Institutional Investors (FIIs) | 20.3% |
| Domestic Institutional Investors (DIIs) | 5.5% |
| Public Shareholding | 7.4% |
The Piramal Group, led by Mr. Ajay Piramal, retains a significant stake, primarily through collective ownership under various group entities. The promoter group’s commanding share of 66.8% underscores their strategic influence over company operations and decision-making processes.
Recent Developments
In June 2023, Piramal Pharma announced the acquisition of a generic injectables portfolio from a U.S.-based company for approximately $180 million. This acquisition aims to enhance their product offerings in the injectables segment, demonstrating the company's growth strategy.
Institutional Investors
Among institutional investors, FIIs have shown considerable interest in Piramal Pharma. As of the latest filings, renowned institutions such as BlackRock and HDFC Mutual Fund hold substantial stakes, reflecting confidence in the company's growth trajectory and financial health.
Stock Performance
Piramal Pharma Limited is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). As of October 2023, the stock is trading at approximately ₹1,050, representing a year-to-date increase of around 15%. The market capitalization stands at approximately ₹42,000 crore.
Governance and Leadership
The governance structure of Piramal Pharma Limited is exemplary. The board comprises seasoned professionals with extensive experience in pharmaceuticals and healthcare. The company emphasizes transparency, with regular disclosures and adherence to regulatory norms, fostering a robust relationship with shareholders.
Ownership of Piramal Pharma Ltd. reflects a mix of strategic long-term investors and active institutional players, positioning the company for further expansion in the competitive pharmaceutical landscape.
Piramal Pharma Limited Mission Statement
Piramal Pharma Limited aims to leverage its strong presence in the pharmaceutical sector to provide innovative and affordable healthcare solutions globally. The company emphasizes quality, accessibility, and sustainability in its operations. Its mission is to "transform lives by providing innovative and affordable healthcare solutions," highlighting a commitment to advancing healthcare outcomes.
Piramal Pharma operates through two primary segments: Piramal Pharma Solutions and Piramal Pharma Retail. The company focuses on enhancing patient access to medications while ensuring the highest standards of quality. This mission is reflected in various financial outcomes and strategic initiatives aimed at expanding its portfolio and market presence.
| Segment | Revenue FY 2023 (in INR Crores) | Growth Rate (YoY) | Strategic Focus |
|---|---|---|---|
| Piramal Pharma Solutions | 2,275 | 15% | Contract Development and Manufacturing |
| Piramal Pharma Retail | 1,200 | 12% | Prescription and Over-the-Counter Products |
| Overall | 3,475 | 13% | Global Expansion and R&D |
In its continuous effort to fulfill this mission, Piramal Pharma has invested significantly in research and development. As of FY 2023, R&D expenditure accounted for approximately 8% of total revenue, which signifies a commitment to innovation. The company also aims to increase its generic product offerings, especially in the US and European markets, recognizing the growing demand for affordable healthcare solutions.
Piramal Pharma's strategic initiatives also include partnerships and collaborations to enhance its product offerings and market reach. In 2023, the company entered into a joint venture with a leading biotech firm, aiming to develop novel therapies. Such partnerships not only align with the mission statement but also strengthen the company's position in the competitive landscape.
The company's operational focus is underscored by its commitment to sustainability and ethical practices. Piramal Pharma has set ambitious targets for reducing its carbon footprint, with a goal of achieving 50% GHG emissions reduction by 2030, ensuring that its mission of providing healthcare is also environmentally responsible.
Moreover, with a workforce of over 10,000 employees globally, Piramal Pharma emphasizes a culture of integrity and teamwork, fostering an environment conducive to innovation and excellence in service delivery. The company's mission is not only about delivering products but also about enhancing the quality of life for patients worldwide.
How Piramal Pharma Limited Works
Piramal Pharma Limited operates primarily in the healthcare sector, focusing on manufacturing and marketing pharmaceutical products. The company is divided into two major segments: Consumer Products and Pharmaceuticals. As of the latest financial year ending March 2023, Piramal Pharma Limited reported revenue of ₹3,064 crore, with a year-over-year growth rate of approximately 15%.
The Pharmaceuticals segment accounts for the bulk of the company’s revenue, contributing about 88% of total sales. This segment includes formulations, active pharmaceutical ingredients (APIs), and contract development and manufacturing services (CDMO). For the year, the Pharmaceuticals segment generated ₹2,694 crore in revenue, demonstrating notable resilience in a challenging market.
The Consumer Products segment, which includes over-the-counter (OTC) products, recorded revenues of ₹370 crore, growing at a rate of around 9% compared to the previous year.
Piramal Pharma Limited has established a strong global presence, exporting products to over 100 countries. The company’s manufacturing facilities are compliant with stringent global regulatory requirements, including certifications from the US FDA, EMA, and WHO. The total number of production facilities stands at 12, strategically located to serve various markets effectively.
| Segment | Revenue (FY 2022-23) | Growth Rate |
|---|---|---|
| Pharmaceuticals | ₹2,694 crore | 15% |
| Consumer Products | ₹370 crore | 9% |
| Total Revenue | ₹3,064 crore | 15% |
Piramal Pharma has been actively investing in research and development (R&D), allocating around 6% of its revenue towards R&D efforts. The focus of R&D includes developing innovative formulations and enhancing the efficacy and safety of existing products. Furthermore, the R&D pipeline boasts over 25 projects at various stages, aimed at addressing prevalent therapeutic areas like oncology and cardiovascular diseases.
In terms of operational efficiency, the company has maintained a healthy EBITDA margin of approximately 24% in the last fiscal year. The net profit for the year was recorded at ₹302 crore, reflecting a net profit margin of about 10%.
Piramal Pharma Limited also emphasizes strategic partnerships to bolster its market position. It has entered into collaborations with several research institutions and other pharmaceutical companies to foster innovation and expand market reach. As of March 2023, the company had formed partnerships with over 15 entities globally, which has helped in enhancing product offerings and accelerating market entry for new drugs.
On the stock market, Piramal Pharma trades on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE). As of the last trading session, the stock price was approximately ₹950 per share, with a market capitalization of around ₹24,000 crore. The stock has experienced a price increase of about 25% year-to-date, reflecting investor confidence in the company's growth prospects.
How Piramal Pharma Limited Makes Money
Piramal Pharma Limited operates in the pharmaceutical sector, primarily generating revenue through two key business segments: Pharmaceutical Solutions and Consumer Products. As of the end of FY 2022, the company's consolidated revenue stood at approximately INR 4,950 crores, demonstrating a growth of 14% year-over-year.
Pharmaceutical Solutions
This segment is focused on contract development and manufacturing, offering a variety of services including drug formulation development and the production of active pharmaceutical ingredients (APIs). In FY 2022, Pharmaceutical Solutions contributed around INR 3,500 crores to the company's revenue.
Consumer Products
The Consumer Products division includes over-the-counter (OTC) products, dietary supplements, and products for ophthalmology and other therapeutic areas. This segment generated about INR 1,450 crores in FY 2022, reflecting a robust growth trajectory.
Key Financial Metrics
| Metric | FY 2022 | FY 2021 | Change (%) |
|---|---|---|---|
| Consolidated Revenue (INR crores) | 4,950 | 4,346 | 14% |
| Pharmaceutical Solutions Revenue (INR crores) | 3,500 | 3,000 | 16.67% |
| Consumer Products Revenue (INR crores) | 1,450 | 1,346 | 7.72% |
| EBITDA (INR crores) | 1,250 | 1,058 | 18.21% |
| Net Profit (INR crores) | 650 | 535 | 21.47% |
Market Position and Strategy
Piramal Pharma is strategically positioned to leverage its integrated business model, focusing on innovation and expanding its global footprint. The company operates in over 100 countries and has over 20 manufacturing facilities worldwide. As of 2023, Piramal Pharma is focused on increasing its presence in the regulated markets, particularly in North America and Europe.
Research and Development (R&D) Investments
The company dedicates a significant portion of its revenue to R&D, with an investment of around INR 500 crores in FY 2022, which equates to approximately 10% of its revenue. This investment supports the development of new drugs and enhances its offering in contract manufacturing.
Recent Developments
In mid-2023, Piramal Pharma announced a strategic partnership with a global biotech firm, aimed at co-developing innovative therapies in oncology and neurology. This partnership is expected to yield significant revenue streams in the coming years, targeting a market valued at over USD 30 billion.
Growth Drivers
The company's growth is driven by several factors including:
- Expansion in the U.S. pharmaceutical market.
- Increasing demand for high-quality APIs.
- Strategic acquisitions to bolster capabilities.
- Focus on chronic and lifestyle diseases in Consumer Products.
Overall, Piramal Pharma Limited's diversified revenue streams, strategic partnerships, and continuous investment in innovation position the company favorably within the competitive pharmaceutical landscape.
Piramal Pharma Limited (PPLPHARMA.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.